GSK pledges £44M to UK biotech to explore fibrosis regression
GSK’s latest hepatology partnership is posing a less-asked question—how do you encourage the regression of patients’ liver fibrosis?…
Can liver fibrosis be undone? Engitix, GSK aim to find out
New collaboration shifts the focus from slowing liver damage to understanding how scarred tissue may heal itself. “The…
Engitix Announces Strategic Collaboration with GSK to Advance First-in-Class Targets for Liver Fibrosis Regression
Collaboration leverages Engitix’s human ECM Platform to identify high-confidence targets for liver fibrosis regression LONDON, June 08, 2026…